SCHEMBL26516539

SCHEMBL26516539

CS(=O)(=O)N(c1cc(Br)cnc1Br)S(C)(=O)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.36
KMT2A Q03164 2/20 0.35
HTT P42858 1/20 0.35
NPC1 O15118 1/20 0.32
EDNRA P25101 1/20 0.32
MEN1 O00255 1/20 0.30
AURKA O14965 1/20 0.30
DAPK3 O43293 1/20 0.30
JAK2 O60674 1/20 0.30
PRKD3 O94806 1/20 0.30
MAP4K4 O95819 1/20 0.30
PAK4 O96013 1/20 0.30
ABL1 P00519 1/20 0.30
NTRK1 P04629 1/20 0.30
FYN P06241 1/20 0.30
RET P07949 1/20 0.30
MET P08581 1/20 0.30
PDGFRB P09619 1/20 0.30
PIM1 P11309 1/20 0.30
FGFR1 P11362 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116319 0.84 HSD17B10 (0.35) HSD17B10KMT2AHTTNPC1EDNRA
SCHEMBL117014 0.82 ALDH1A1 (0.37) HSD17B10KMT2AHTTNPC1EDNRA
SCHEMBL1118864 0.80 SHMT2 (0.33) HSD17B10KMT2AEDNRAMEN1
SCHEMBL2067485 0.73 PIK3C3 (0.45) HSD17B10KMT2ANPC1EDNRAMEN1
SCHEMBL18824500 0.71 NPC1 (0.41) HSD17B10KMT2AHTTNPC1MEN1
SCHEMBL856141 0.70 PIK3CA (0.41) HSD17B10KMT2AHTTEDNRAMEN1
SCHEMBL16914055 0.70 KMT2A (0.44) HSD17B10KMT2AHTTNPC1MEN1
SCHEMBL15053192 0.69 EDNRA (0.39) HSD17B10KMT2AHTTNPC1EDNRA
SCHEMBL22574365 0.68 CYP19A1 (0.36) HSD17B10KMT2AEDNRAMEN1PTK2
SCHEMBL16914002 0.68 EDNRA (0.38) HSD17B10KMT2ANPC1EDNRAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 US disclosed
CN-117858877-A C-linked inhibitors of ENL/AF9 YEATS 桥梁药品有限公司 2024-04-09 CN disclosed
EP-4337662-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS Bridge Medicines (US) 2024-03-20 EP disclosed
US-20230322770-A1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL MYERS SQUIBB CO (US) 2023-10-12 US disclosed
US-20230322770-A1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL MYERS SQUIBB CO (US) 2023-10-12 US disclosed
EP-4200015-A1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 Bristol-Myers Squibb Company (US) 2023-06-28 EP disclosed
CN-115956077-A Substituted heteroaryl compounds as TLR9 inhibitors 百时美施贵宝公司 2023-04-11 CN disclosed
WO-2022240830-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES (US) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322770-A1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 TLR9, TLR3, TLR1 HSD17B10 3808/4885KMT2A 609/4885HTT 3713/4885
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 HSD17B10 2328/4885KMT2A 53/4885HTT 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.